
BioNTech bags Instadeep for £562m
According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

Vésale Bioscience wins R&D grant
Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...

Novo Holdings invests into standardisation of LC-MS-based proteomics
Novo Holdings, the investment arm of Nordisk A/S has invested €40m in the eight-years-old clinical proteomics specialist Ecosep Aps to benefit from...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

CatalYm GmbH raises €50m to push visugromab development
Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...